Equity Profile

CHE

Chemed Corporation

Health CareHealth Care Services$7.0B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Chemed Corporation operates in the health care sector, primarily providing hospice and palliative care services. With a market cap of $7 billion, the company plays a crucial role in delivering compassionate care to patients with serious illnesses, which is increasingly important as the population ages.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to exceed previous quarters, reflecting operational efficiency.

Revenue Growth

Revenue growth signals the company's ability to expand its services and capture market share in the health care sector.

Expected to show positive trends based on historical performance.

Wall Street expectations, options signals, track record, and call prep available with Pro.

CHE Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+2.95%

Avg Stock Reaction

+0.49%

Last Quarter Recap

In Q1-2026, Chemed reported an EPS of $5.65, beating expectations by 16.49%. The stock reacted positively, gaining 2.63% the following day.

Management Promises & Guidance

Focus on enhancing patient care services.
Commitment to improving operational efficiencies.
Plans to expand service offerings in key markets.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Chemed's upcoming earnings, expecting continued growth in EPS and revenue. However, the lack of specific guidance raises some uncertainty.

Bull Case

If Chemed beats EPS estimates again, it could signal strong operational performance and market confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to exceed previous quarters, reflecting operational efficiency.

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Expected to show positive trends based on historical performance.

Revenue growth signals the company's ability to expand its services and capture market share in the health care sector.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for this quarter?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

How does management plan to address revenue growth challenges?

Understanding management's strategy for growth will be essential for assessing the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Chemed's ability to leverage its operational efficiencies to drive higher margins, despite potential revenue challenges.

Supporting Evidence

The company has a history of beating EPS estimates, suggesting strong management execution.

Options pricing indicates a significant move, which may reflect investor uncertainty rather than a bearish outlook.

Key Risk

If EPS comes in below $5.50, it could undermine confidence in the company's growth strategy.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Chemed's ability to sustain growth in a competitive health care environment.

Bull Confirmed If

An EPS of $6.00 or higher would confirm the bullish outlook and suggest strong operational performance.

Bear Confirmed If

An EPS below $5.50 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±13.24%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±13.2% while CHE has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

33.0%

Calls (400)P/C Ratio: 0.33Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Chemed beats expectations, history suggests the stock could rise by around 0.76% on the first day after the report.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see little movement as investors digest the information.

Miss

A miss could lead to a decline of approximately 0.33%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on operational efficiency improvements.
2Details on revenue growth strategies in key markets.
3Management's outlook on future earnings and market conditions.
4Insights into patient care service expansions.
5Responses to competitive pressures in the health care sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to exceed previous quarters, reflecting operational efficiency.

Revenue Growth

Revenue growth signals the company's ability to expand its services and capture market share in the health care sector.

Expected to show positive trends based on historical performance.

Wall Street expectations, options signals, track record, and call prep available with Pro.

CHE Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+2.95%

Avg Stock Reaction

+0.49%

Last Quarter Recap

In Q1-2026, Chemed reported an EPS of $5.65, beating expectations by 16.49%. The stock reacted positively, gaining 2.63% the following day.

Management Promises & Guidance

Focus on enhancing patient care services.
Commitment to improving operational efficiencies.
Plans to expand service offerings in key markets.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Chemed's upcoming earnings, expecting continued growth in EPS and revenue. However, the lack of specific guidance raises some uncertainty.

Bull Case

If Chemed beats EPS estimates again, it could signal strong operational performance and market confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to exceed previous quarters, reflecting operational efficiency.

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Expected to show positive trends based on historical performance.

Revenue growth signals the company's ability to expand its services and capture market share in the health care sector.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for this quarter?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

How does management plan to address revenue growth challenges?

Understanding management's strategy for growth will be essential for assessing the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Chemed's ability to leverage its operational efficiencies to drive higher margins, despite potential revenue challenges.

Supporting Evidence

The company has a history of beating EPS estimates, suggesting strong management execution.

Options pricing indicates a significant move, which may reflect investor uncertainty rather than a bearish outlook.

Key Risk

If EPS comes in below $5.50, it could undermine confidence in the company's growth strategy.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Chemed's ability to sustain growth in a competitive health care environment.

Bull Confirmed If

An EPS of $6.00 or higher would confirm the bullish outlook and suggest strong operational performance.

Bear Confirmed If

An EPS below $5.50 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±13.24%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±13.2% while CHE has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

33.0%

Calls (400)P/C Ratio: 0.33Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Chemed beats expectations, history suggests the stock could rise by around 0.76% on the first day after the report.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see little movement as investors digest the information.

Miss

A miss could lead to a decline of approximately 0.33%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on operational efficiency improvements.
2Details on revenue growth strategies in key markets.
3Management's outlook on future earnings and market conditions.
4Insights into patient care service expansions.
5Responses to competitive pressures in the health care sector.